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We evaluated the therapeutic usefulness of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer
(NSCLC). We also examined the relation between DNA ploidy pattern and the response to chemotherapy. A total of 267 patients
with NSCLC (pathologically documented stage I, II, or IIIA) underwent complete resection, and DNA ploidy pattern was analysed.
Patients with stage I disease (n¼172) were randomly assigned to receive surgery alone (group A) or surgery followed by adjuvant
chemotherapy (UFT (oral anti-cancer drug, a combination of Uracil and Tegaful) 400mg day
 1 for 1 year after surgery; group B).
Stage II or IIIA disease patients (n¼95) were randomly assigned to surgery alone (group C) or surgery followed by chemotherapy
(two 28-day courses of cisplatin 80mgm
 2 on day 1 plus vindesine 3mgm
 2 on days 1 and 8, followed by UFT 400mgday
 1 for at
least 1 year; group D). Eight-year overall survival rate in patients with stage I disease was 74.2% (95% confidence interval (CI): 64.4–
84.0%) in group B and 57.6% (95% CI: 46.4–68.8%) in group A (P¼0.045 by log-rank test). In patients with stage II and IIIA disease,
no difference was found between groups C and D. Analysis according to DNA ploidy pattern revealed no difference between the
groups. Postoperative chemotherapy with UFT was suggested to be useful in patients with completely resected stage I NSCLC. No
difference was seen in relation to DNA pattern in any treatment group.
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A meta-analysis of postoperative chemotherapy in non-small cell
lung cancer (NSCLC) reported by the British Medical Council in
1995 found that adjuvant chemotherapy did not adequately
improve outcome in this condition (Non-small Cell Lung Cancer
Collaborative Group, 1995). Despite a number of trials since, the
value of postoperative chemotherapy for NSCLC remains con-
troversial (Wada et al, 1996; Endo et al, 2003; Scagliotti et al, 2003).
Beginning around 1990, considerable attention has been focused
on DNA ploidy pattern as a possible new prognostic factor, with
tumours showing aneuploidy, associated with a poor prognosis,
reported to show a better response to chemotherapy than those
showing diploidy (Granone et al, 1993; Salvati et al, 1994; Kim
et al, 1996). However, these previous studies were based on
retrospective data.
Here, we investigated the usefulness of postoperative adjuvant
chemotherapy for the management of NSCLC patients prospec-
tively assigned to treatment on the basis of DNA ploidy.
PATIENTS AND METHODS
Eligibility criteria
Eligibility criteria included an untreated primary lung cancer;
histologically confirmed diagnosis of squamous cell carcinoma,
adenocarcinoma, or large cell carcinoma; pathologically documen-
ted stage I, II, or IIIA disease; diploidy or aneuploidy on analysis of
nuclear DNA of the primary tumour; age 75 years or younger in
patients with stage I disease or 70 years or younger in those with
stage II or IIIA disease; Eastern Cooperative Oncology Group
(ECOG) performance status of 0, 1, or 2; and adequate organ
function as defined by a leucocyte count of at least 4000mm
 3,
platelet count of at least 100000mm
 3, serum haemoglobin level of
at least 10gdl
 1, serum aspartate aminotransferase (AST) level of
not more than 100U, alanine aminotransferase (ALT) level of at
most 100U, albumin/globulin ratio of at least 1.0, serum creatinine
level of less than 1.5mgdl
 1, and serum urea nitrogen level of not
Received 5 May 2006; revised 27 July 2006; accepted 27 July 2006;
published online 12 September 2006
*Correspondence: Dr K Nakagawa;
E-mail: katuhiro@hbk.pref.osaka.jp
We dedicate this paper to the late Dr Takashi Mori, who died before
completion of the study.
See Appendix.
British Journal of Cancer (2006) 95, 817–821
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
smore than 25mgdl
 1. Further, patients with a serious concurrent
condition were also excluded. All tumours were resected by
pulmonary resection consisting of at least lobectomy and
systematic hilar/mediastinal lymph node dissection. Cases of
complete resection were defined as those without macroscopic
residual tumour or microscopic positive margins. The study was
reviewed and approved by the institutional review boards of each
participating centre, and written informed consent was obtained
from all patients.
Because stage I disease differs considerably from stage II and
IIIA disease, assignment of similar treatments would have
negatively affected outcome. Patients with stage II or IIIA disease
were therefore assigned to receive different treatment from those
with stage I disease.
Measurement of DNA ploidy
Samples were harvested and frozen immediately after tumour
excision. Nuclear DNA content was measured by flow cytometry
and evaluated by an independent flow cytometry evaluation
committee who were blinded to patient data.
Treatment schedule
Patients were grouped according to stage as follows. For stage I
patients, Group A (control) received no adjuvant chemotherapy
but was followed after surgery, whereas Group B received single
daily oral administration of UFT (oral anti-cancer drug, a
combination of Uracil and Tegaful) at 400mgday
 1 for at least 1
year starting 3–6 weeks after surgery.
For stages II and IIIA, Group C (control) received no adjuvant
chemotherapy but was followed after surgery, whereas Group D
was given two 28-day courses of chemotherapy with cisplatin
(80mgm
 2) on day 1 and vindesine (3mgm
 2) on days 1 and 8,
starting 3–6 weeks after surgery, followed by single daily oral
administration of UFT at 400mgday
 1 for at least 1 year.
Adverse effects of chemotherapy were evaluated using the
National Cancer Institute Common Toxicity Criteria (version 2.0,
Jan 30, 1998) and handled by appropriate treatment, discontinua-
tion of UFT, or both. In Group D, chemotherapy after the
administration of vindesine on day 8 of the first course was
continued only after confirmation that white blood cell count was
greater than 3000. Other anticancer drugs, immunomodulators,
and radiotherapy were not used unless recurrence was confirmed.
Treatment assignment
Patients were stratified on the basis of pathological stage,
histologic type, and ploidy pattern, and then randomly assigned
to groups. Randomisation was performed centrally, with assign-
ment for pathological T and N stage balanced using the
minimisation method with probability and the method of Zelen
(Yonekura et al, 1999; Tanaka et al, 2002).
Statistical analysis
The primary end point was overall survival, defined as the time
from surgery until death from any cause. The secondary end point
was disease-free survival, defined as the time from surgery until
relapse or death from any cause, whichever occurred first.
Survival curves were calculated by the Kaplan–Meier method
(Kaplan and Meier, 1958), and statistical significance of differences
between groups was compared with the log-rank test (Peto et al,
1977). P-values of less than 0.05 were considered to indicate
significance. Multivariable analysis to estimate the simultaneous
effects of prognostic factors on survival was carried out with the
Cox proportional-hazards model. Categorical variables were
compared using the w
2 test.
Target numbers of patients were calculated as follows. Based on
previous studies (Kuwahara et al, 1989; The Study Group of
Adjuvant Chemotherapy for Lung Cancer, 1995; Wada et al, 1996),
the assumed 5-year survival in the control group was 75% in stage
I patients and 40% in stage II or III patients. The expected survival
improvement was 15% in stage I patients and 25% in stage II or III
patients.
On the basis of Freedman’s sample size table (Freedman, 1982),
the sample size required to detect a significant difference between
surgery alone and surgery plus chemotherapy at a power of 0.8 and
a 5% level of significance was 169 patients with stage I disease and
102 with stage II, or III disease.
One goal of this study was to compare survival in patients with
aneuploid tumours who received chemotherapy after surgery with
that in patients who received surgery alone. Given an aneuploid to
diploid tumour ratio of 8:2 (Yamaoka et al, 1991), 80% of stage I,
II, and III cases were estimated to be aneuploid. The required
number of cases was therefore estimated to be 212 cases of stage I
disease and 128 cases of stage II or III disease. Allowing for 8%
ineligibility and loss to follow-up, the target number was set at 230
patients with stage I and 140 with stage II or III disease.
All statistical analyses were carried out using the SAS software
package ver. 7 (SAS Institute Inc, Cary, NC, USA).
RESULTS
A total of 287 patients were enrolled at 15 centres from April 1992
to March 1994. At this time, a number of new induction
chemotherapy protocols for early stage lung cancer were
introduced in Japan, hampering the further accrual of patients,
and enrollment was therefore stopped in March 1994. This report
evaluates cases followed until the end of November 2001.
Of the 287 patients enrolled, 20 were excluded because they did
not meet the entry criteria, namely conditions other than cancer
(inflammatory or benign tumours) or non-curative resection.
Median follow-up time of the 267 patients studied was 7.4 years.
Clinical characteristics
Of 172 patients with stage I disease, 87 were assigned to group A
and 85 to group B, with no significant difference between them in
sex, mean age, performance status, T stage, histologic type, or
tumour DNA pattern.
Of 95 patients with stage II (n¼33) or IIIA (n¼62) disease, 48
were assigned to group C and 47 to group D, with no significant
difference between them in sex, mean age, performance status, T
stage, N stage, pathologically determined disease stage, histologic
type, or DNA pattern (Table 1).
Treatment rate
A 100% treatment rate was defined as at least 1 year of continuous
treatment with 400mg of UFT daily. From this, individual rates
were calculated as (number of UFT administration days)/
365 (daily UFT dosage)/400 100. Mean treatment rates in
groups B and D were estimated to be 76.7 and 48.6%, respectively.
In group D, 39 patients were given one or more courses of cisplatin
and vindesine (one course in three patients, two in 36). Treatment
compliance was 83.0%. Treatment was not given to eight patients
owing to patient refusal in two, postoperative complications in
two, and poor general condition in four.
Survival rate
Eight-year overall survival rate in stage I patients was 57.6% (95%
confidence interval (CI): 46.4–68.8%) in group A (control) and
74.2% (95% CI: 64.4–84.0%) in group B, with a significant
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sdifference seen between the two survival curves (P¼0.045;
Figure 1). Respective rates in Groups C and D were 36.8% (95%
CI: 21.3–52.3%) and 38.0% (95% CI: 23.5–52.5%), with no
significant difference between these two overall survival curves
(P¼0.52). Moreover, no significant difference was seen in 8-year
disease-free survival rate between groups A and B or C and D.
Subgroup analyses
When subgrouped by histology, the adenocarcinoma subgroup
showed no significant difference in overall survival curves between
groups A and B (P¼0.065); or between patients in groups A and B
with diploid tumours (P¼0.078) or aneuploid tumours (P¼0.16)
(Table 2). Moreover, overall survival curves in this adenocarcino-
ma subgroup did not differ significantly between groups C and D
(group C, n¼29, 8-year survival rate 41.3%, 95% CI: 21.9–60.7%;
group D, n¼27, 8-year survival rate 40.0%, 95% CI: 19.9–60.0%;
P¼0.98).
When subgrouped by DNA pattern, no significant difference in
overall survival curve was seen in diploid tumour patients in
groups C and D (group C, n¼10, 8-year survival rate 30.0%, 95%
CI: 1.6–58.4%; group D, n¼8, 8-year survival rate 37.5%, 95% CI:
4.0–71.0%; P¼0.92); or between aneuploid patients in groups C
and D (group C, n¼38, 8-year survival rate 36.8%, 95% CI: 17.8–
55.8%; group D, n¼39, 8-year survival rate 38.1%, 95% CI: 21.8–
54.4%; P¼0.44).
Multivariate analysis
Multivariate analysis indicated that UFT treatment was a
significant predictor of outcome in stage I patients, following age
and sex (Table 3).
Adverse effects
Grade 3 anorexia occurred in one patient in group B. The
incidence of grade 3 and 4 toxicity was only 1.2% in group B. In
Table 1 Patient characteristics
A B Total C D Total
No. of eligible patients 87 85 172 48 47 95
Sex
Male 49 49 98 35 35 70
Female 38 36 74 13 12 25
Age
(Ave.) 60.9 60.2 60.6 59.3 60.5 59.9
PS
0 66 66 132 36 35 71
1 1 91 9 3 81 21 0 2 2
22 0 2 0 2 2
pT
1 4 14 5 8 61 21 3 2 5
2 4 64 0 8 62 42 4 4 8
31 2 1 0 2 2
pN
06 1 7
11 8 1 9 3 7
22 4 2 7 5 1
Stage
I 87 85 172
II 16 17 33
IIIA 32 30 62
Histology
Adenocarcinoma 67 68 135 29 27 56
Squamous cell carcinoma 17 15 32 17 17 34
Large cell carcinoma 3 2 5 2 3 5
DNA pattern
Diploidy 18 17 35 10 8 18
Aneuploidy 69 68 137 38 39 77
Abbreviations: PS, performance status; pT, pathological tumour stage; pN,
pathological lymph node stage.
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Figure 1 Overall survival of stage I control and UFT group patients.
Eight-year survival rate was 57.6% for the control group A (n¼87) and
74.2% for the UFT group B (n¼85). A significant difference in survival
curves for these groups is seen (P¼0.045 by log-rank test).
Table 2 Overall survival in the control and UFT groups
No. of cases 8-year survival rate (%)
AB A B P-value
Sex
Female 38 36 74.7 78.0 0.850
Male 49 49 43.6 71.6 0.013
Age (years)
o60 38 37 74.5 84.8 0.171
X60 49 48 45.9 65.4 0.153
PS
0 66 66 62.0 78.3 0.055
1, 2 21 19 43.4 62.2 0.460
pT
T1 41 44 56.4 87.7 0.014
T2 46 40 59.4 58.5 0.763
Histology
Adeno carcinoma 67 68 60.2 75.6 0.065
Non-adeno carcinoma 20 17 51.7 69.3 0.503
DNA pattern
Diploidy 18 17 53.5 86.7 0.078
Aneuploidy 69 68 59.0 71.3 0.158
Abbreviations: PS, performance status; pT, pathological tumour stage.
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(14.6%), anorexia in three patients (6.3%), nausea/vomiting in two
patients (4.2%), and hair loss in one patient (2.1%) (Table 4). No
episode lasted more than 1 month.
There were no lethal adverse effects in either chemotherapy
group.
Mortality
Twenty-six of 87 patients (29.9%) in group A and 14 of 85 (16.5%)
in group B died of their tumours, with this difference being
significant (P¼0.037). Nine patients in group A and six in group B
died of causes other than cancer, with this difference not
significant (P¼0.45).
The rate of mortality from cancer was 52.1% in group C and
42.6% in group D, with this difference not significant (P¼0.35).
The rate of mortality from other causes was 6.3% in group C and
17.0% in group D, again without significance (P¼0.10).
DISCUSSION
UFT is an oral fluorinated dihydropyrimidine preparation which
combines tegafur, a prodrug of 5-fluorouracil, with uracil, an
inhibitor of dihydropyrimidine dehydrogenase, the enzyme which
catalyses the metabolism of 5-fluorouracil. One reason for the
effectiveness of postoperative adjuvant chemotherapy with UFT in
patients with completely resected stage I lung cancer is the action
of tegafur. The metabolism of tegafur results in prolongation of
active levels of 5-fluorouracil, and its metabolites (GHB and GBL)
promote angiogenesis (Yonekura et al, 1999; Basaki et al, 2001;
Tanaka et al, 2002). Meta-analysis of several randomised
controlled studies has confirmed that UFT is therapeutically
useful. The Japan Lung Cancer Research Group (JLCRG)
performed Phase III randomised controlled studies of post-
operative adjuvant chemotherapy with UFT in patients with stage
I adenocarcinoma of the lung, and showed significant improval in
survival, with a hazard ratio of 0.71 (95% CI: 0.52–0.98) as
compared with surgery alone in this subgroup (P¼0.04) (Kato
et al, 2004).
Our study enrolled a wider range of patients than the JLCRG
study, including not only adenocarcinoma and completely resected
stage I NSCLC, but also stage II and IIIA NSCLC. Survival in
patients with stage I disease was significantly better in group B
than in group A (P¼0.045). On analysis by histologic tumour type,
survival in patients with adenocarcinoma was slightly but not
significantly better in group B (P¼0.065). In contrast, survival in
patients with diploid tumours did not differ between group A and
B, probably because of the low patient numbers, which were
insufficient for statistical analysis (n¼18 and 17, respectively).
The number of patients with diploid tumour was small as
compared with that of patients with aneuploid tumour, and was
insufficient for statistical analysis in the present study.
In stage II and III adenocarcinoma, in contrast, no difference in
survival was seen either overall, or by ploidy. These results
therefore suggest that UFT is effective for the management of stage
I lung cancer, consistent with the findings of the WJSG 2nd study
and the JLCRG study (Kato et al, 2004).
Early studies of DNA ploidy (Granone et al, 1993; Salvati et al,
1994; Kim et al, 1996) reported that aneuploidy is an independent
predictor of poor outcome. In contrast, more recent investigations
(Fujino et al, 1996; Bellotti et al, 1997; Reinmuth et al, 2000;
Pelletier et al, 2001) have questioned the value of ploidy as a
prognostic factor. Statistical analysis of the prognostic implica-
tions of diploidy was precluded in the present study owing to the
low number of patients with diploid tumours (stage I, n¼35; stage
II and III, n¼18).
With regard to the efficacy of the present therapeutic regimen, a
meta-analysis of the usefulness of postoperative cisplatin-based
adjuvant chemotherapy in NSCLC found good efficacy in stage II
and III patients receiving cisplatin-based (320mgm
 2 or more)
chemotherapy with vinorelbine (Pignon et al, 2006). In contrast,
the dose of cisplatin in the present study was as low as 160mgm
 2
and vindesine was used as a combination drug. These differences
Table 3 Multivariate analysis of outcomes
Factor Hazard ratio 95% CI P-value
Sex
Female 1
Male 1.95 1.11–3.60 0.019
Age (years)
o60 1
X60 2.24 1.26–4.20 0.0053
Group
Control 1
UFT 0.57 0.32–0.97 0.039
Table 4 Toxicity
UFT CDDP+VDS+UFT
Grade Grade
Toxicity (n¼85) 1 2 3 4 Frequency of G3 or G4 (%) Toxicity (n¼47) 1 2 3 4 Frequency of G3 or G4 (%)
Leucopenia 8 2 0 0 Leucopenia 8 11 5 2 14.6
Thrombocytopenia 2 0 0 0 Thrombocytopenia 3 2 0 0
Anaemia 1 0 0 0 Anaemia 8 6 0 0
AST 6 0 0 0 GOT 6 3 0 0
ALT 5 2 0 0 GPT 9 4 0 0
Anorexia 10 8 1 0 1.2 BUN 5 0 0 0
Nausea/vomiting 8 1 0 0 Creatinine 2 0 0 0
Diarrhoea 3 1 0 0 Anorexia 10 14 3 0 6.3
Stomatitis 4 0 0 0 Nausea/vomiting 12 4 2 0 4.2
Pigmentation 6 0 0 0 Diarrhoea 4 1 0 0
Alopecia 0 1 0 0 Stomatitis 4 0 0 0
Alopecia 7 7 1 0 2.1
Abbreviations: BUN, blood urea nitrogen; CDDP, cisplatin; VDS, vindesine sulfate.
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Further, the response rate to UFT in unresectable NSCLC has been
reported as only 8% (Keicho et al, 1986), and usefulness of
postoperative adjuvant chemotherapy has been described for
relatively early-stage NSCLC only. The possibility therefore exists
that UFT may have insufficient efficacy in stage II/III disease with
high malignancy.
In conclusion, although the relation between DNA
ploidy pattern and the response to postoperative adjuvant
chemotherapy remains unclear, our results suggest that
postoperative adjuvant chemotherapy with UFT improves survival
and is therapeutically useful in patients with completely resected
stage I NSCLC.
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